Barrow Hanley Mewhinney & Strauss LLC purchased a new stake in shares of Humana Inc. (NYSE:HUM - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 792,814 shares of the insurance provider's stock, valued at approximately $314,922,000. Barrow Hanley Mewhinney & Strauss LLC owned approximately 0.66% of Humana at the end of the most recent reporting period.
A number of other hedge funds have also modified their holdings of the company. Montag A & Associates Inc. lifted its stake in shares of Humana by 1,880.0% during the 4th quarter. Montag A & Associates Inc. now owns 99 shares of the insurance provider's stock valued at $25,000 after buying an additional 94 shares in the last quarter. Johnson Financial Group Inc. purchased a new stake in Humana in the 2nd quarter worth $26,000. Fideuram Asset Management Ireland dac bought a new stake in Humana during the fourth quarter valued at about $27,000. Trust Co. of Vermont bought a new stake in Humana during the second quarter valued at about $28,000. Finally, Reflection Asset Management purchased a new position in shares of Humana in the fourth quarter valued at about $29,000. 92.38% of the stock is currently owned by institutional investors.
Humana Stock Performance
NYSE:HUM opened at $379.22 on Monday. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.74 and a quick ratio of 1.74. Humana Inc. has a 1 year low of $163.11 and a 1 year high of $428.88. The stock's 50 day simple moving average is $383.38 and its two-hundred day simple moving average is $282.25. The company has a market cap of $45.54 billion, a price-to-earnings ratio of 35.88, a PEG ratio of 2.17 and a beta of 0.72.
Humana (NYSE:HUM - Get Free Report) last posted its earnings results on Wednesday, July 29th. The insurance provider reported $7.61 EPS for the quarter, beating analysts' consensus estimates of $7.27 by $0.34. The firm had revenue of $40.89 billion during the quarter, compared to the consensus estimate of $40.58 billion. Humana had a return on equity of 11.20% and a net margin of 0.88%.The company's quarterly revenue was up 26.2% compared to the same quarter last year. During the same period in the prior year, the company earned $6.27 EPS. As a group, equities analysts anticipate that Humana Inc. will post 9.08 earnings per share for the current fiscal year.
Analysts Set New Price Targets
HUM has been the subject of a number of recent analyst reports. Wells Fargo & Company raised Humana from an "equal weight" rating to an "overweight" rating and upped their price objective for the stock from $227.00 to $502.00 in a research note on Monday, July 13th. UBS Group initiated coverage on Humana in a report on Thursday, July 30th. They issued a "buy" rating on the stock. Barclays upped their price target on Humana from $344.00 to $407.00 and gave the stock an "equal weight" rating in a research note on Friday, July 31st. Oppenheimer reaffirmed an "outperform" rating and set a $405.00 price objective on shares of Humana in a report on Thursday, July 30th. Finally, HSBC cut shares of Humana to a "hold" rating in a research report on Thursday, July 30th. Fourteen equities research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $395.22.
Check Out Our Latest Stock Report on Humana
Humana Company Profile
(
Free Report)
Humana Inc NYSE: HUM is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana's products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.
In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.
Featured Articles
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Humana, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humana wasn't on the list.
While Humana currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
